binding molecule of IGF plays a critical role in regulating IGF function. 5 The relationships between IGFBP-3 and some cancers have been reported. Serum IGFBP-3 levels in lung cancer patients were found to be lower than those of controls; 6 however, in breast cancer, IGFBP-3 expression induced mammary cell growth. 7 Tas also reported that serum IGFBP-3 might be a complement marker for CA125 in epithelial ovarian cancer diagnosis. 8 In addition, IGFBP-3 expression was found to be lower in pancreatic cancer patients than that of controls. 9 However, the relationship between serum IGFBP-3 and CRC has not been reported yet.
Previous reports have indicated that the IGF system played an important role in CRC cell proliferation. 10, 11 However, the clinical significance of serum IGFBP-3 level in CRC patients has not yet been reported. The present study aimed to measure serum IGFBP-3 levels in CRC patients and investigate the clinical significance of serum IGFBP-3 in CRC. 
| MATERIAL S AND ME THODS

| Subjects
| Sample collection
Venous blood (2.0 mL) was collected from each subject into tubes without anticoagulant. Serum was separated by centrifugation at 2000 g for 10 minutes, and samples were stored at −80°C until use.
| Serum IGFBP-3 and CEA measurement
Serum IGFBP-3 levels were measured using chemiluminescence immunoassay (Immulite 1000, Siemens Healthcare Diagnostics Inc,), and serum CEA levels were measured using electrogenerated chemiluminescence immunoassay (Cobas E602, Roche Diagnostics).
| Statistical analysis
The normality of data was checked by the Kolmogorov-Smirnov test, and the data were not normally distributed. Serum IGFBP-3 levels were summarized as median (interquartile range). Results were compared between groups using the Mann-Whitney U test. The relationships between serum IGFBP-3 and CEA were investigated by using binary logistic regression analysis. A receiver operating characteristic (ROC) curve was plotted to determine the area under the curve (AUC), sensitivity, and specificity of serum IGFBP-3 and CEA levels for CRC, respectively. Statistical analysis was performed using SPSS 13.0 software (Chicago, IL, USA), and P < 0.05 represented a statistically significant result.
| RE SULTS
| Patient clinical characteristics
A total of 70 CRC patients were enrolled in the study. The clinical characteristics are summarized in Table 1 . Those characteristics included gender, the information of CRC patients with diabetes mellitus (DM), TNM stage, and the status of lymph node metastasis and tumor differentiation and are listed in Table 1 Figure 1B ).
| Relationships between serum IGFBP-3 and CRC clinical characteristics
Patients with early stages (I and II) and lymph node metastasis absent showed higher serum IGFBP-3 levels than those of patients with advanced stages (III and IV) and lymph node metastasis present 
| Relationships between serum CEA and IGFBP-3
No significant associations were found between serum IGFBP-3 and CEA levels (r = 0.092, P = 0.48; Figure 3 ). The result indicated that serum IGFBP-3 might be a complementary marker for CEA, especially for patients with normal serum CEA levels.
| Diagnostic efficacy of serum IGFBP-3 for CRC
The ROC curve for serum IGFBP-3 level in CRC ( Figure 4) 
| D ISCUSS I ON
CRC is one of the most frequently diagnosed types of cancer.
Previous studies have indicated that an increased risk of CRC might be associated with insulin-like growth factors. [13] [14] [15] Previous reports indicated that IGF system played an important role in the pathological process of cancer. 16 IGFBP-3 as a member of IGF system has been demonstrated to play an important role in various cancers, including non-small-cell lung cancer, hepatocellular carcinoma, ovarian cancer, breast cancer, and gastric cancer. 17 Yan et al 18 found that IGFBP-3 expression levels were lower in hepatocellular carcinoma tissues than those of adjacent nonmalignant liver tissue and low IGFBP-3 levels were associated with high cancer risk, poor prognosis, and tumor metastasis in esophageal cancer. 19 Keku et al 20 reported that IGFBP-3 gene expression was significantly lower in CRC tissue than that of normal colorectal tissue. Similarly, the present study indicated that serum IGFBP-3 was lower in CRC patients than that of controls. All these studies indicated that serum IGFBP-3 might be a potential biomarker for CRC.
Most CRCs are first diagnosed at an advanced stage in most cases. A better biomarker was expected to be closed with clinical characteristics. Previous reports indicated that higher IGFBP-3 levels were closely associated with earlier clinical stages in esophageal squamous cell carcinoma. 21 Yan et al found that in HCC tissue, IGFBP-3 expression levels were inversely correlated with tumor size, node metastasis, and clinical stage. 18 Zhao et al reported that the clinical pathological stage of esophageal cancer was inversely associated with serum IGFBP-3 levels. 22 Keku found that IGFBP-3 mRNA levels were positively associated with apoptosis in CRC tissue, but in normal colonic tissue, no significant association was found between IGFBP-3 mRNA levels and apoptosis. 20 Our study indicated that serum IGFBP-3 level was negatively correlated with CRC tumor stage and lymph node metastasis. Although the statistical difference in serum IGFBP-3 levels was not found between different tumor CEA, a tumor marker, has been widely used for CRC diagnosis in clinical practice. 23 However, CEA expression has been found to be increased in certain noncancerous conditions, such as ulcerative colitis. 24 The serum CEA level frequently increases several months before CRC recurrence and has been widely used as a marker for predicting CRC recurrence. 25 But some patients showed high serum CEA levels despite the absence of CRC recurrence, while in others the serum CEA level is positive at initial surgery but becomes negative at the In conclusion, serum IGFBP-3 levels in CRC were significantly lower than those in controls and were closely correlated with CRC stage and lymph node metastasis. ROC analysis indicated that a combination of serum IGFBP-3 and CEA level is a potential tool for CRC.
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